This site is intended for Healthcare Professionals only

HCV: DAAs reduce deaths and cancer

Clinical bookmark icon off

HCV: DAAs reduce deaths and cancer

Direct-acting antivirals (DAA) seem to reduce mortality and hepatocellular carcinoma in people with chronic hepatitis C virus (HCV) infection, the Lancet reports.

French researchers followed 9,895 patients with chronic HCV for a median of 33.4 months. During this time, 7,344 patients received DAAs. Of those with known status and sufficient follow-up, 94 per cent overall and 92 per cent of patients with cirrhosis at baseline showed sustained virological responses.

During follow-up, 129 DAA-treated people and 89 untreated patients died, 187 and 71 respectively developed hepatocellular carcinoma, while 74 and 32 respectively showed decompensated cirrhosis. After adjusting for confounders, using DAA decreased all-cause mortality by 52 per cent and hepatocellular carcinoma by 34 per cent.

In the 3,045 patients with cirrhosis at baseline, DAAs were associated with a 66 per cent decline in all-cause mortality and a 72 per cent reduction in liver-related mortality. The risk of nonliver- related mortality and hepatocellular carcinoma fell by 60 and 43 per cent respectively. People who did not show a sustained virological response were more than twice as likely (hazard ratio 2.23) to develop hepatocellular carcinoma.

DAAs were not associated with decompensated cirrhosis. In people with cirrhosis at baseline and a sustained virological response, DAAs reduced the risk of decompensated cirrhosis by 49 per cent. This reduction was not significant, probably because of a lack of statistical power.

“Taking a large cohort like this provides the opportunity to evaluate the effect of directacting antiviral therapy on the long-term outcomes of patients with hepatitis C,” says lead author Professor Fabrice Carrat of Sorbonne University, Paris. “We saw a reduction of risk for complications related to the disease and to mortality, and believe this treatment should be considered for all patients with chronic hepatitis C infection.”

Copy Link Record my learning outcomes
Save for later bookmark icon off

Clinical

Let’s get clinical. Follow the links below to find out more about the latest clinical insight in community pharmacy.

Share: